A number of other equities analysts also recently commented on CRSP. Chardan Capital reiterated a buy rating and issued a $72.50 price target on shares of Crispr Therapeutics in a research note on Monday, November 18th. Roth Capital lifted their target price on Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Oppenheimer lifted their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a research note on Monday, November 25th. Wells Fargo & Co restated a buy rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Finally, Canaccord Genuity boosted their price objective on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a research report on Wednesday, November 20th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $75.95.
NASDAQ:CRSP opened at $51.95 on Thursday. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -112.93 and a beta of 3.20. Crispr Therapeutics has a one year low of $29.34 and a one year high of $74.00. The stock has a 50-day simple moving average of $61.06 and a 200 day simple moving average of $52.69. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
In related news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at $412,500. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,618 shares of company stock worth $3,230,760. 21.40% of the stock is currently owned by corporate insiders.
Institutional investors have recently modified their holdings of the business. Farmers & Merchants Trust Co of Chambersburg PA bought a new position in shares of Crispr Therapeutics during the 4th quarter valued at approximately $26,000. State Street Corp increased its stake in Crispr Therapeutics by 2.1% in the third quarter. State Street Corp now owns 37,103 shares of the company’s stock worth $1,521,000 after purchasing an additional 758 shares during the period. Webster Bank N. A. purchased a new stake in Crispr Therapeutics in the fourth quarter worth $26,000. Millennium Management LLC bought a new position in shares of Crispr Therapeutics during the 3rd quarter worth $4,366,000. Finally, Exchange Traded Concepts LLC bought a new position in shares of Crispr Therapeutics during the 4th quarter worth $54,000. 49.84% of the stock is currently owned by hedge funds and other institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Sell-Side Analysts
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.